February 11, 2025

Skin Manifestations of COVID: IFN-1 Link Found

Pseudochilblains were linked to exaggerated IFN-1 production by plasmacytoid dendritic cells, according to new findings on COVID-19-related skin diseases.

Conexiant

February 10, 2025

Weight Loss Drugs Reshape Facial Surgery: Survey

AAFPRS survey reveals GLP-1 medications drive 50% increase in fat-grafting procedures as patients seek solutions for weight loss-related facial volume loss.

Conexiant

February 07, 2025

Hematologic Indicators Linked to Alopecia Areata Severity

Researchers analyze hematological ratios in alopecia areata severity assessment.

Conexiant

February 07, 2025

24-Month Study Shows Ritlecitinib Efficacy in Alopecia

73.5% of patients achieved a SALT score ≤ 20 after 24 months of ritlecitinib treatment, according to new phase III findings.

Conexiant

February 05, 2025

Predictive Rituximab Protocol Reduces Pemphigus Relapse Risk

French multicenter study demonstrates targeted rituximab maintenance therapy guided by clinical and serological markers cuts early pemphigus relapse rates from 17.6% to 2.6%

Conexiant

February 05, 2025

Medical Oddities: Resist the Itch? Maybe Not

Scratching an itch may have positive and negative outcomes. Compounds in tomatoes may work as an antidepressant. Selenoproteins help keep blood young. And more.

Conexiant

February 05, 2025

Wearable Device Reduces Nighttime Scratching

A new study in JAMA Dermatology unveiled a wearable device with haptic feedback that significantly reduced nocturnal scratching in mild atopic dermatitis patients, offering a potential nonpharmacologic intervention.

Conexiant

February 05, 2025

New Study Explores COVID-19’s Dermatologic Impact

More than 20% of COVID-19 patients experience skin conditions, ranging from rashes to pseudochilblains, linked to immune response.

Conexiant

February 04, 2025

Health Agencies Face Lawsuit Over Data Removal

A medical advocacy group sues U.S. health agencies over the removal of public health data in response to an executive order targeting 'gender ideology extremism.' The lawsuit seeks to reinstate the removed webpages and challenges an OPM memorandum, naming the CDC, FDA, and HHS as defendants.

Reuters